Monoclonal anti-endotoxin antibodies for the treatment of gram-negative bacteremia and septic shock (original) (raw)

References

  1. Kreger BE, Craven DE, Carling PC, McCabe WR: Gram-negative bacteremia. III: Reassessment of etiology, epidemiology and ecology in 612 patients. American Journal of Medicine 1980, 68: 332–343.
    Article PubMed Google Scholar
  2. McGowan JE, Barnes MW, Finland M: Bacteremia at Boston City Hospital: occurrence and mortality during 12 selected years (1935–1972) with special reference to hospital-acquired cases. Journal of Infectious Diseases 1975, 132: 326–341.
    Google Scholar
  3. Bryan CS, Reynolds KL, Brenner ER: Analysis of 1,186 episodes of gram-negative bacteremia in nonuniversity hospitals: the effects of antimicrobial therapy. Reviews of Infectious Diseases 1983, 5: 629–638.
    PubMed Google Scholar
  4. Bone RG, Fisher CJ, Clemmer TP: A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. New England Journal of Medicine 1987, 317: 653–658.
    PubMed Google Scholar
  5. Calandra T, Glauser MP, Schellekens J, Verhoef J, andthe Swiss-Dutch J5 Immunoglobulin Study Group: Treatment of gram-negative septic shock with human IgG antibody to_Escherichia coli_ J5: a prospective, double-blind, randomized study. Journal of Infectious Diseases 1988, 158: 312–319.
    PubMed Google Scholar
  6. The Veterans Administration Systemic Sepsis Cooperative Study Group: Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. New England Journal of Medicine 1987, 317: 659–665.
    Google Scholar
  7. De Maria A, Craven DE, Heffernan JJ, McIntosh TK, Grindlinger GA, McCabe WR: Naloxone versus placebo in treatment of septic shock. Lancet 1985, i: 1363–1365.
    Article Google Scholar
  8. Pollack M, Chia JKS, Koles NL, Miller M, Guelde G: Specificity and cross-reactivity of monoclonal antibodies reactive with the core and lipid A regions of bacterial lipopolysaccharide. Journal of Infectious Diseases 1989, 159: 168–188.
    PubMed Google Scholar
  9. Jansson PE, Lindberg AA, Lindberg B, Wollin R: Structural studies on the hexose region of the core in lipopolysaccharides from_Enterobacteriaceae_. European Journal of Biochemistry 1981, 115: 571–577.
    PubMed Google Scholar
  10. Kirkland TN, Ziegler EJ: An immunoprotective monoclonal antibody to lipopolysaccharide. Journal of Immunology 1984, 132: 2590–2592.
    Google Scholar
  11. Pennington JE: Impact of molecular biology on_Pseudomonas aeruginosa_ immunization. Journal of Hospital Infection 1988, 11, Supplement: 96–102.
    Article PubMed Google Scholar
  12. Hector RF, Collins MS, Pennington JE: Treatment of experimental_Pseudomonas aeruginosa_ pneumonia with a human IgM monoclonal antibody. Journal of Infectious Diseases 1989, 160: 483–489.
    PubMed Google Scholar
  13. Chedid L, Parant M, Parant F, Boyer F: A proposed mechanism for natural immunity to enterobacterial pathogens. Journal of Immunology 1968, 100: 292–301.
    Google Scholar
  14. Braude AI, Douglas H: Passive immunization against the local Shwartzman reaction. Journal of Immunology 1972, 108: 505–512.
    Google Scholar
  15. McCabe WR: Immunization with R mutants of_Salmonella minnesota_. I: Protection against challenge with heterologous gram-negative bacilli. Journal of Immunology 1972, 108: 601–610.
    Google Scholar
  16. Ziegler EJ, McCutchan JA, Fierer J, Glauser MP, Sadoff JC, Douglas H, Braude AI: Treatment of gram-negative bacteremia and shock with human antiserum to a mutant_Escherichia coli_. New England Journal of Medicine 1982, 307: 1225–1230.
    PubMed Google Scholar
  17. Baumgartner JD, Glauser MP, McCutchan JA, Ziegler EJ, van Melle G, Klauber MR, Vogt M, Muehlen E, Lüthy R, Chiolero R, Geroulanos S: Prevention of gram-negative shock and death in surgical patients by prophylactic antibody to endotoxin core glycolipid. Lancet 1985, ii: 59–63.
    Article Google Scholar
  18. Baumgartner JD, Glauser MP: Immunotherapy of gram-negative septic shock. In: Vincent JL (ed): Update in intensive care and emergency medicine. Update 1990. Springer Verlag, Berlin, 1990, p. 109–120.
    Google Scholar
  19. McCutchan JA, Wolf JL, Ziegler EJ, Braude AI: Ineffectiveness of single-dose human antiserum to core glycolipid (Escherichia coli J5) for prophylaxis of bacteremic, gram-negative infection in patients with prolonged neutropenia. Schweizer Medizinische Wochenschrift 113, 14, Supplement: 40–45.
  20. Appelmelk BJ, Verweij-von Vught AMJJ, Maaskant JJ, Schouten WF, Thijs LG, MacLaren DM: Monoclonal antibodies detecting novel structures in the core region of_Salmonella minnesota_ lipopolysaccharide. FEMS Microbiology Letters 1987, 40: 71–74.
    Article Google Scholar
  21. Pollack M, Raubitschek AA, Larrick JW: Human monoclonal antibodies that recognize conserved epitopes in the core-lipid A region lipopolysaccharides. Journal of Clinical Investigations 1987, 79: 1421–1430.
    Google Scholar
  22. Teng NNH, Kaplan HS, Hebert JM: Protection against gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies. Proceedings of the National Academy of Science of the USA 1985, 82: 1790–1794.
    Google Scholar
  23. Young LS, Gascon R, Alam S, Bermudez LE: Monoclonal antibodies for treatment of gram-negative infections. Reviews of Infectious Diseases 1989, 11, Supplement 7: 1564–1571.
    Google Scholar
  24. Kirkland TN, Colwell DE, Michalek SM, McGhee JR, Ziegler EJ: Analysis of the fine specificity and cross-reactivity of monoclonal anti-lipid A antibodies. Journal of Immunology 1986, 137: 3614–3619.
    Google Scholar
  25. Mutharia LM, Crockford G, Bogard C, Hancock REW: Monoclonal antibodies specific for_Escherichia coli_ J5 lipopolysaccharide: cross-reaction with other gram-negative bacterial species. Infection and Immunity 1984, 45: 631–636.
    PubMed Google Scholar
  26. Miner KM, Manyak CL, Williams E: Characterization of murine monoclonal antibodies to_Escherichia coli_ J5. Infection and Immunity 1986, 52: 56–62.
    PubMed Google Scholar
  27. Young LS: Functional activity of monoclonal antibodies against lipopolysaccharide antigens of gram-negative bacilli. Clinical Research 1984, 32: 518A.
  28. Ziegler E, Fisher C, Sprung C, Straube R, Sadoff J, and the HA-1A Sepsis Study Group: Prevention of death from gram-negative bacteremia and sepsis by HA-1A, a human monoclonal antibody specific for lipid A of endotoxin: results of phase III trial. Clinical Research 1990, 38: 304A.
  29. Baumgartner JD, Heumann D, Gerain J, Weinbreck P, Grau GE, Glauser MP: Association between in vivo suppression of LPS-induced tumor necrosis factor and protective efficacy of anti-LPS antibodies: role of O-side-chains-specific compared to core LPS antibodies. Journal of Experimental Medicine 1990, 171: 889–896.
    Article PubMed Google Scholar
  30. Westphal O, Jann K, Himmelspach K: Chemistry and immunochemistry of bacterial lipopolysaccharides as cell wall antigens and endotoxins. Progress in Allergy 1983, 33: 9–39.
    PubMed Google Scholar

Download references